Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor - AstraZeneca

Drug Profile

Ticagrelor - AstraZeneca

Alternative Names: AR-C-126532; AZD-6140; Brilinta; Brilique

Latest Information Update: 10 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
  • Class Antianaemics; Antibacterials; Antithrombotics; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Ribonucleosides; Small molecules; Vascular disorder therapies
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Cardiovascular disorders; Sickle cell anaemia; Stroke
  • Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 10 Nov 2018 Efficay and adverse events data from the phase III PEGASUS-TIMI 54 trial in Ischemic heart disease (IHD) presented at the 91st Annual Scientific Sessions of the American Heart Association (AHA-2018)
  • 26 Sep 2018 Phase-III clinical trials in Sickle cell anaemia (In children, In adolescents) in Spain, Belgium (PO) (NCT03615924)
  • 25 Aug 2018 Additional adverse events data from the phase III PLATO trial in Acute coronary syndromes presented at the Annual Congress of the European Society of Cardiology (ESC-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top